Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo

Lilly has exceeded market expectations due to strong demand for its injectable GLP-1 drugs, resulting in an increased competitive advantage over Novo.

Summarised by a model from Reuters's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.

On file here

Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.

What the headline doesn't tell you

• This story is about a class — GLP-1 and incretin therapies — rather than one compound. We track 14 compounds in it, holding 344 studies between them, 150 in humans.

Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.